Calquence

• Brands Calquence
• Product Code: Calquence

• Calquence (acalabrutinib) is a Bruton’s tyrosine kinase (BTK) inhibitor, a type of targeted therapy used to treat B-cell malignancies—cancers that affect a type of white blood cell called B lymphocytes.

  It works by blocking BTK, an enzyme essential for B-cell receptor signaling, which cancerous B cells rely on for growth, survival, and spread. By inhibiting this pathway, Calquence helps slow or stop the progression of cancer.

  FDA-approved uses:

  • Chronic lymphocytic leukemia (CLL)

  • Small lymphocytic lymphoma (SLL)

  • Mantle cell lymphoma (MCL) (for adults who have received at least one prior therapy)

  Administration:

  • Taken orally, usually 100 mg twice daily, with or without food

  • Capsules should be swallowed whole (not crushed or chewed)

  Common side effects:

  • Headache

  • Diarrhea

  • Fatigue

  • Muscle aches

  • Bruising

  Serious risks:

  • Infections

  • Bleeding complications

  • Atrial fibrillation and other heart rhythm issues

  • Cytopenias (low blood cell counts)

  Calquence is often better tolerated than older BTK inhibitors like ibrutinib, with potentially fewer cardiovascular side effects.

• Availability: In Stock

• American Diabetes Association

• Diabetes Disaster_Response Coalition storing insulin

• FDA Approved Prescription